Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27900208 | 0.94 | MAOB (0.63) | TAAR1MAOBMIFIDO1KIF11 | |
| SCHEMBL5544769 | 0.88 | TAAR1 (0.50) | TAAR1MAOBMIFIDO1KMT2A | |
| SCHEMBL1119524 | 0.86 | TAAR1 (0.57) | TAAR1MAOBMIFIDO1HDAC1 | |
| SCHEMBL934227 | 0.85 | TAAR1 (0.73) | TAAR1MAOBMIFIDO1HDAC1 | |
| SCHEMBL1046291 | 0.85 | TAAR1 (0.55) | TAAR1MAOBMIFIDO1HDAC1 | |
| SCHEMBL1047874 | 0.83 | TAAR1 (0.53) | TAAR1MAOBMIFIDO1HDAC1 | |
| SCHEMBL18378241 | 0.82 | TAAR1 (0.42) | TAAR1MAOBMIFIDO1HDAC1 | |
| SCHEMBL127709 | 0.80 | TAAR1 (0.54) | TAAR1MAOBMIFIDO1KDM4E | |
| SCHEMBL2092697 | 0.80 | MAOB (0.58) | TAAR1MAOBMIFIDO1HDAC1 | |
| SCHEMBL2745550 | 0.79 | GFER (0.42) | TAAR1MAOBKDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023237580-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2023-12-14 | — | — | WO | claimed |
| US-20190053492-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2019-02-21 | — | — | US | claimed |
| EP-3429997-A1 | N-(CYANOBENZYL)-6-(CYCLOPROPYL-CARBONYLAMINO)-4-(PHENYL)-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PESTICIDES AND PLANT PROTECTION AGENTS | Bayer CropScience Aktiengesellschaft (DE) | 2019-01-23 | — | — | EP | claimed |
| CN-109071444-A | N- (cyanobenzyl) -6- (cyclopropyl-carbonylamino) -4- (phenyl) -pyridine-2-carboxamide derivatives and related compounds as pesticides and plant protection agents | 拜耳作物科学股份公司 | 2018-12-21 | — | — | CN | claimed |
| WO-2017157885-A1 | N-(CYANOBENZYL)-6-(CYCLOPROPYL-CARBONYLAMINO)-4-(PHENYL)-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PESTICIDES AND PLANT PROTECTION AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-09-21 | — | — | WO | claimed |
| CN-101163504-A | Combination therapy | XENON PHARMACEUTICALS INC (CA) | 2008-04-16 | — | — | CN | claimed |
| EP-1626043-B1 | Heterocyclic thioesters | MGI GP INC (US) | 2007-12-12 | — | — | EP | claimed |
| CN-1829690-A | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2006-09-06 | — | — | CN | claimed |
| EP-1083873-B1 | HETEROCYCLIC THIOESTER AND KETONE HAIR GROWTH COMPOSITIONS AND USES | MGI GP INC (US) | 2006-08-09 | — | — | EP | claimed |
| EP-1626043-A1 | Heterocyclic thioesters | MGI GP, Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| US-6274602-B1 | ADMINISTERING COMPOSTITIONS SUCH AS 3,3-DIMETHYL-1-((2S)-2-(5-(3-PYRIDYL) PENTANOYL)-1-PYRROLIDINE)-1, 2-PENTANEDIONE TO TREAT ALOPECIA OR PROMOTING HAIR GROWTH IN ANIMALS | GPI NIL HOLDINGS, INC. | 2001-08-14 | — | — | US | claimed |
| EP-1104298-A2 | HETEROCYCLIC THIOESTERS OR KETONES FOR VISION AND MEMORY DISORDERS | GPI NIL Holdings, Inc. (US) | 2001-06-06 | — | — | EP | claimed |
| JP-2001506231-A | — | — | 2001-05-15 | — | — | JP | claimed |
| EP-1083873-A1 | HETEROCYCLIC THIOESTER AND KETONE HAIR GROWTH COMPOSITIONS AND USES | GPI NIL Holdings, Inc. (US) | 2001-03-21 | — | — | EP | claimed |
| US-6172064-B1 | METALLOPROTEASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIDIABETIC AGENTS; ANTITUMOR AGENTS | GLAXO WELLCOME INC. | 2001-01-09 | — | — | US | claimed |
| WO-2000009479-A2 | HETEROCYCLIC THIOESTERS OR KETONES FOR VISION AND MEMORY DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2000-02-24 | — | — | WO | claimed |
| WO-1999062488-A1 | HETEROCYCLIC THIOESTER AND KETONE HAIR GROWTH COMPOSITIONS AND USES | GPI NIL HOLDINGS, INC. (US) | 1999-12-09 | — | — | WO | claimed |
| US-5990131-A | OF GIVEN FORMULA WHICH HAVE A HIGH AFFINITY FOR FKBPS (FK506 BINDING PROTEINS, A CLASS OF IMMUNOPHILINS) ARE POTENT ROTAMASE INHIBITORS AND EXHIBIT EXCELLENT NEUROTROPHIC EFFECTS; NO IMMUNOSUPPRESSIVE ACTIVITY | GPI NIL HOLDINGS INC. (US) | 1999-11-23 | — | — | US | claimed |
| EP-0934263-A1 | HETEROCYCLIC THIOESTERS AND KETONES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-08-11 | — | — | EP | claimed |
| WO-1998013343-A1 | HETEROCYCLIC THIOESTERS AND KETONES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190053492-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS PESTICIDES | CHRM1, CHRM2, ACHE | TAAR1 205/4885MAOB 1165/4885MIF 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.